Nintedanib for the treatment of non-small-cell lung cancer

Sawsan Rashdan, Nasser Hanna

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Introduction: In NSCLC, increased microvessel count, often used as a measure of angiogenesis, has been correlated with poor prognosis and associated with advanced disease and inferior outcomes. In the clinical development of antiangiogenic therapies, two approaches have been used; the first has been to inhibit ligand binding and receptor activation using targeted antibodies, whereas the second has been to inhibit receptor activation using tyrosine kinase inhibitors that target VEGF receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and/or fibroblast growth factor receptor (FGFR). Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR, PDGFR and FGFR. It has shown significant antiangiogenic and antineoplastic activities in vitro, in preventing tumor growth and overcoming drug resistance. Areas covered: Medline search was used with the following keywords: non-small-cell lung cancer and nintedanib or BIBF 1120, ASCO abstracts 2013 with nintedanib, and Phase I and Phase II abstracts lung cancer and nintedanib. Expert opinion: Recent Phase III trials have shown promising efficacy results of nintedanib in NSCLC; however, many questions still need to be answered before it is put into routine use.

Original languageEnglish
Pages (from-to)729-739
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Platelet-Derived Growth Factor Receptors
Fibroblast Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor
Expert Testimony
Microvessels
Drug Resistance
Antineoplastic Agents
Protein-Tyrosine Kinases
nintedanib
Lung Neoplasms
Ligands
Antibodies
Growth
Neoplasms

Keywords

  • Angiogenesis
  • Fibroblast growth factor
  • Nintedanib
  • NSCLC
  • Platelet-derived growth factor
  • Tyrosine kinase inhibitors
  • VEGF

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Nintedanib for the treatment of non-small-cell lung cancer. / Rashdan, Sawsan; Hanna, Nasser.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 5, 2014, p. 729-739.

Research output: Contribution to journalArticle

@article{365b539446404700a1909b2dc06d5662,
title = "Nintedanib for the treatment of non-small-cell lung cancer",
abstract = "Introduction: In NSCLC, increased microvessel count, often used as a measure of angiogenesis, has been correlated with poor prognosis and associated with advanced disease and inferior outcomes. In the clinical development of antiangiogenic therapies, two approaches have been used; the first has been to inhibit ligand binding and receptor activation using targeted antibodies, whereas the second has been to inhibit receptor activation using tyrosine kinase inhibitors that target VEGF receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and/or fibroblast growth factor receptor (FGFR). Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR, PDGFR and FGFR. It has shown significant antiangiogenic and antineoplastic activities in vitro, in preventing tumor growth and overcoming drug resistance. Areas covered: Medline search was used with the following keywords: non-small-cell lung cancer and nintedanib or BIBF 1120, ASCO abstracts 2013 with nintedanib, and Phase I and Phase II abstracts lung cancer and nintedanib. Expert opinion: Recent Phase III trials have shown promising efficacy results of nintedanib in NSCLC; however, many questions still need to be answered before it is put into routine use.",
keywords = "Angiogenesis, Fibroblast growth factor, Nintedanib, NSCLC, Platelet-derived growth factor, Tyrosine kinase inhibitors, VEGF",
author = "Sawsan Rashdan and Nasser Hanna",
year = "2014",
doi = "10.1517/14656566.2014.897695",
language = "English",
volume = "15",
pages = "729--739",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Nintedanib for the treatment of non-small-cell lung cancer

AU - Rashdan, Sawsan

AU - Hanna, Nasser

PY - 2014

Y1 - 2014

N2 - Introduction: In NSCLC, increased microvessel count, often used as a measure of angiogenesis, has been correlated with poor prognosis and associated with advanced disease and inferior outcomes. In the clinical development of antiangiogenic therapies, two approaches have been used; the first has been to inhibit ligand binding and receptor activation using targeted antibodies, whereas the second has been to inhibit receptor activation using tyrosine kinase inhibitors that target VEGF receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and/or fibroblast growth factor receptor (FGFR). Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR, PDGFR and FGFR. It has shown significant antiangiogenic and antineoplastic activities in vitro, in preventing tumor growth and overcoming drug resistance. Areas covered: Medline search was used with the following keywords: non-small-cell lung cancer and nintedanib or BIBF 1120, ASCO abstracts 2013 with nintedanib, and Phase I and Phase II abstracts lung cancer and nintedanib. Expert opinion: Recent Phase III trials have shown promising efficacy results of nintedanib in NSCLC; however, many questions still need to be answered before it is put into routine use.

AB - Introduction: In NSCLC, increased microvessel count, often used as a measure of angiogenesis, has been correlated with poor prognosis and associated with advanced disease and inferior outcomes. In the clinical development of antiangiogenic therapies, two approaches have been used; the first has been to inhibit ligand binding and receptor activation using targeted antibodies, whereas the second has been to inhibit receptor activation using tyrosine kinase inhibitors that target VEGF receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and/or fibroblast growth factor receptor (FGFR). Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR, PDGFR and FGFR. It has shown significant antiangiogenic and antineoplastic activities in vitro, in preventing tumor growth and overcoming drug resistance. Areas covered: Medline search was used with the following keywords: non-small-cell lung cancer and nintedanib or BIBF 1120, ASCO abstracts 2013 with nintedanib, and Phase I and Phase II abstracts lung cancer and nintedanib. Expert opinion: Recent Phase III trials have shown promising efficacy results of nintedanib in NSCLC; however, many questions still need to be answered before it is put into routine use.

KW - Angiogenesis

KW - Fibroblast growth factor

KW - Nintedanib

KW - NSCLC

KW - Platelet-derived growth factor

KW - Tyrosine kinase inhibitors

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84896258821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896258821&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.897695

DO - 10.1517/14656566.2014.897695

M3 - Article

C2 - 24597846

AN - SCOPUS:84896258821

VL - 15

SP - 729

EP - 739

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -